Glucose Medipharm

Glucose Medipharm is a sterile injectable solution containing glucose monohydrate. It is supplied in an unspecified strength for the European market. Classified as a carbohydrate excipient for parenteral nutrition, it is prescription‑only. The formulation is designed for intravenous use to raise glucose levels and support fluid balance during treatment.

Glucose Medipharm is indicated for several clinical situations where rapid carbohydrate delivery is required to correct low blood sugar, provide energy in parenteral nutrition, or assist with fluid management.

- Treatment of documented hypoglycemia in hospital or emergency settings. - Component of total parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid replacement therapy when isotonic carbohydrate solutions are needed. - Support for patients undergoing surgery or critical illness who require controlled glucose infusion. - Adjunct in diagnostic procedures that require intravenous glucose loading.

Glucose Medipharm, like other intravenous carbohydrate solutions, may be associated with a range of adverse effects, most of which are related to its metabolic and osmotic properties.

Common: - Transient increase in blood glucose levels. - Mild hyperosmolarity leading to temporary thirst. - Local irritation at the injection site. - Nausea or mild abdominal discomfort.

Serious: - Severe hyperglycemia requiring insulin therapy. - Electrolyte disturbances such as hyponatremia. - Fluid overload with risk of pulmonary edema. - Allergic reactions ranging from rash to anaphylaxis.

When using Glucose Medipharm, clinicians should observe specific precautions to minimize risks and ensure appropriate therapeutic outcomes.

- Verify blood glucose concentration before and during infusion. - Adjust infusion rate in patients with renal or cardiac insufficiency. - Monitor electrolyte levels, especially sodium and potassium, during prolonged therapy. - Use caution in individuals with diabetes mellitus or impaired glucose tolerance. - Avoid rapid infusion in neonates and small children due to risk of hyperosmolar injury. - Ensure compatibility with other intravenous solutions before co‑administration.

Glucose Medipharm can interact with other medications or solutions, influencing glucose metabolism or fluid balance, therefore awareness of potential interactions is essential.

Avoid: - Concurrent administration with high‑dose insulin without close glucose monitoring. - Mixing with calcium‑containing solutions that may precipitate. - Co‑infusion with hypertonic saline solutions that could exacerbate hyperosmolarity.

Use with caution: - Concurrent use of diuretics that may alter electrolyte status. - Administration alongside beta‑blockers, which can mask hypoglycemia symptoms. - Co‑administration with other carbohydrate‑containing parenterals, requiring total glucose load calculation.